Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

In This Issue

J Immunol July 1, 2019, 203 (1) 1; DOI: https://doi.org/10.4049/jimmunol.1990010
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Inhibiting Drug Allergy with Engineered Small Molecules

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Allergic reactions to drugs, such as penicillin, can occur when they covalently attach to carrier proteins and then, in turn, the complex binds IgE. In this issue, Deak et al. (p. 21) describe the inhibition of allergic responses to penicillin using specifically engineered covalent heterobivalent inhibitors (cHBI). cHBIs were engineered to irreversibly bind Ag-specific IgE, as revealed by ELISA and flow cytometry. cHBI treatment was able to inhibit degranulation responses for allergen concentrations up to 2 μg/ml and reduced the allergic reaction of mice sensitized with drug allergens. This inhibition was both time and dose dependent, with inhibition lasting at least 72 h. Additionally, mice sensitized to drug allergen and treated prophylactically with cHBIs demonstrated resistance to allergic reaction 16 h after treatment. These data indicate that cHBIs can specifically reduce allergic reactivity toward known drug allergens and, therefore, provide a promising clinical avenue for the treatment of drug allergy.

Thymus-Derived, Bone Marrow to Thrive

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Whereas mainstream αβT cells develop in the thymus via TCR-mediated selection, the involvement of coreceptors in the selection of minor T cell subsets with invariant TCRs remains elusive. In this issue, Yamamoto et al. (p. 167) found unexpectedly higher (10–15%) proportions of resident double negative T cells in bone marrow (BM) than what was seen in other lymphoid tissues of healthy adult mice. BM-resident DN αβT (BMDNT) cells displayed a diverse TCR repertoire and were thus distinct from known invariant NKT cells. Development of BMDNT cells was dependent on the thymic Notch ligand and IL-7, and was independent of MHC class II, β2-microglobulin–associated MHC class I, CD1d, or MR1. BMDNT cells became detectable after birth and were maintained by homeostatic proliferation through adulthood via myeloid cell–derived IL-1β. BMDNT cells also exhibited functional features of innate lymphoid cells, expressing a series of NK receptors and displaying potent cytotoxic activity and robust activation in the BM following systemic administration of TLR ligands. Together, these results suggest that a unique subset of αβT cells with innate immune function emerges after birth, develops in the thymus by TCR-based positive selection, and is sustained throughout adulthood in the BM.

Boosting Protection

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

The bacillus Calmette–Guérin (BCG) vaccine is a live, attenuated vaccine used to prevent tuberculosis. Recent studies have shown that expression of suppressor of cytokine signaling 1 (SOCS1), a negative regulator of JAK/STAT signaling, is induced during BCG vaccination and may negatively affect the vaccine’s efficacy in protecting against Mycobacterium tuberculosis. In this issue, Mizuno et al. (p. 188) engineered a recombinant BCG secreting a dominant negative mutant of the SOCS1 molecule (rBCG-SOCS1DN). Mice immunized with this vaccine generated M. tuberculosis–specific T cell responses, and produced higher levels of IL-6, TNF-α, and IFN-γ. rBCG-SOCS1DN–vaccinated mice were better protected against M. tuberculosis challenge than mice vaccinated with a control BCG vaccine. These results indicate that a modified BCG vaccine which targets SOCS1 may be a viable approach to improving vaccine efficacy.

Antagonist against Lupus

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

The CD40/CD40L pathway is critical to humoral and cell-mediated immunity and has been linked to multiple pathological conditions associated with systemic lupus erythematosus (SLE). In this issue, Perper et al. (p. 58) developed a rat/mouse chimeric anti-mouse CD40 mAb. Anti-CD40 mAb treatment of mice with existing SLE symptoms significantly reduced severe proteinuria and nephritis and improved survival. However, SLE symptoms returned upon cessation of anti-CD40 mAb treatment, and the therapeutic effect of this mAb on reducing kidney inflammation was dose dependent. Not only did this CD40 antagonist reduce kidney glomerular disease, tubular dilation, and perivascular infiltration, but it was also associated with reduced salivary gland inflammation and restored saliva production. Together, these results indicate that treatment of mice with a CD40 antagonist can improve symptoms associated with murine SLE, which may inform the future development of CD40 antagonists for treating the disease in humans.

  • Copyright © 2019 by The American Association of Immunologists, Inc.
PreviousNext
Back to top

In this issue

The Journal of Immunology: 203 (1)
The Journal of Immunology
Vol. 203, Issue 1
1 Jul 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In This Issue
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In This Issue
The Journal of Immunology July 1, 2019, 203 (1) 1; DOI: 10.4049/jimmunol.1990010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In This Issue
The Journal of Immunology July 1, 2019, 203 (1) 1; DOI: 10.4049/jimmunol.1990010
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Inhibiting Drug Allergy with Engineered Small Molecules
    • Thymus-Derived, Bone Marrow to Thrive
    • Boosting Protection
    • Antagonist against Lupus
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Top Reads
  • In This Issue
  • In This Issue
Show more IN THIS ISSUE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606